ADC Therapeutics’ Post

Evaluate targeted therapeutic options in relapsed/refractory follicular lymphoma with our on-demand webcast. Learn how to implement multidisciplinary team strategies and shared decision-making to select optimal treatment and support patients with R/R FL. Watch now: https://okt.to/iS7AJp

Evaluate targeted therapeutic options in relapsed/refractory follicular lymphoma with our on-demand webcast. Learn how to implement multidisciplinary team strategies and shared decision-making to select optimal treatment and support patients with R/R FL. Watch now: https://okt.to/mgntcY

Check out this great opportunity to join Foresight Diagnostics Inc. Inc. co-founder David Kurtz and our esteemed expert panelists Ryan Lynch and Lara Stepan on March 7th during our webinar to discuss the role of #MRD in #lymphoma clinical development.    Some spoilers:  - Early and accurate response assessment using MRD may accelerate event accrual in clinical trials for earlier endpoint readouts vs. using PFS alone - Retrospective analyses of clinical trial data show MRD predicted deep and durable response even earlier than end of treatment - Clinical utility of MRD includes adjudication of PET/CT to enable more informed decision-making    You can register by clicking on our post below.      #oncology #precisionmedicine #ctdna #clinicaltrials

🏥 Learn more about novel therapies for B-cell lymphoma by watching Dr Marc Hoffmann discuss results of a phase I trial here: https://lnkd.in/eHnHT4-7 #healthbook #healthbooknewsroom #advancingclinicalpractice #lymphomatherapy #clinicaltrials #EHA2024 

PN Update: Orphan designation: 4-[[[4-[5-Chloro-2-[[trans-4-[[(1R)-2-methoxy-1-methyl-ethyl]amino]cyclohexyl]amino]-4-pyridinyl]-2-thiazolyl]amino]methyl]tetrahydro-2H-pyran-4-carbonitrile Treatment of peripheral T-cell lymphoma, 25/07/2024 Positive

Tuesday Tip: When diagnosing lymphoma, the most accessible LN is usually biopsied, but this LN is not always the primary site. Follow the Heme database rules to determine the primary site. https://lnkd.in/g2G7Xb-U. tx_txtra

Two subtypes of cutaneous T-cell lymphoma (#CTCL) - Mycosis Fungoides and Sézary Syndrome - manifest and spread in different ways, including within the blood. Learn more at https://bit.ly/3Z9CSnR #BloodCancerAwarenessMonth

Incyte Features Results from the P-III (inMIND) Trial of Monjuvi (Tafasitamab) to Treat R/R Follicular Lymphoma at ASH 2024  #incyte #monjuvi #tafasitamab #follicularlymphoma #clinicaltrial #ash2024

Inspired by the progress shared at #ASH2024, TFS is proud to have supported a complex CAR T study, preventing life-threatening side effects in lymphoma patients undergoing immunotherapy. Learn more: https://lnkd.in/eKfk6gUx In this case study, discover how TFS advanced immunotherapy through innovative site engagement, proactive risk mitigation, and customized training, ensuring success in a CAR T-cell therapy study in hematologic malignancies despite challenges like drug supply shortages and complex protocols. #OncologyCRO #TogetherWeMakeADifference

This study found that diffuse large B cell lymphoma (DLBCL) resistance to combine therapy rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone (R-CHOP) linked to single nucleotide polymorphisms (SNPs) rs1883112 and rs1800871. These two SNPs can also be used as predictor for prognosis, since the study linked them to shortened progression free survival and overall survival. https://lnkd.in/g3uJVhuh